APTO - Alliance Global Partners initiates a Buy rating for Aptose Biosciences

Aptose Biosciences (APTO) was initiated with a buy rating by Alliance Global Partners analyst Matt Cross, and gave a target price of $12, almost double from current level.Cross mentions in a research note, that the company's pipeline has seen "significant momentum" over the last several quarters, as its two lead therapeutic assets for the treatment of hematologic cancers successfully returned or first entered clinical trials and consequently began to produce "encouraging" activity data in ongoing dose-escalation testing.Shares closed $6.25, +6.1% on Sept. 22.Check out the company's performance against peers over the last one year.Previously: Aptose to launch early-stage CG-806 study in acute myeloid leukemia (June 29)

For further details see:

Alliance Global Partners initiates a Buy rating for Aptose Biosciences